AstraZeneca plc (ADR)

+$0.57 (+0.9%)
Closing price October 22, 2021
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including American Express, Chipotle Mexican Grill, eBay, Nvidia, Qualcomm and Tesla.
Two pharmaceutical companies and a top media firm are on tap to report quarterly results before markets open on Thursday.
America's two largest energy companies report March quarter results Friday morning, along with two big pharmaceutical makers.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including AstraZeneca, Bumble, McDonald’s and Microsoft.
Tuesday's top analyst upgrades and downgrades included Adobe, Altria, AstraZeneca, Crowdstrike, Microsoft, Roblox, Starbucks, Ulta Beauty and Zoom Video Communications.
Thursday's top analyst upgrades and downgrades included AstraZeneca, Dollar General, Lowe’s, Nike, Nvidia, Shopify and Square.
Here’s a preview of four companies that will be reporting quarterly results before the markets open on Thursday.
Top analyst calls seen Friday afternoon were on AstraZeneca, Foot Locker, PayPal, Tesla, Yeti and more.
Alexion Pharmaceutical shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca.
Monday's top analyst upgrades and downgrades included Apple, BP, CrowdStrike, Delta Air Lines, Moody's, NuStar Energy, PPL,, Slack Technologies and Wells Fargo.
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Wednesday's top analyst upgrades and downgrades included AIG, CrowdStrike, Datadog, Devon Energy, eGain, Lyft, Moderna, Occidental Petroleum, Peloton Interactive and Yelp.
Two federal agencies have awarded AstraZeneca some $486 million to develop further the company's treatment and potential vaccine for COVID-19. The payment includes delivery of 100,000 doses of the...
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...